BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19307678)

  • 21. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.
    Kudo M
    Oncology; 2008; 75 Suppl 1():1-12. PubMed ID: 19092266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic therapy for hepatocellular carcinoma.
    Thomas MB
    Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment options for hepatocellular carcinoma.
    Sandhu DS; Tharayil VS; Lai JP; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet count less than SHARP: what does a case series reveal?
    Saif MW
    Expert Opin Drug Saf; 2010 Jan; 9(1):1-8. PubMed ID: 20001607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the treatment response of HCC.
    Kim KW; Lee JM; Choi BI
    Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of hepatocellular carcinoma.
    Lau WY
    J R Coll Surg Edinb; 2002 Feb; 47(1):389-99. PubMed ID: 11874260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of hepatocellular carcinoma.
    Said A; Wells J
    Minerva Med; 2009 Feb; 100(1):51-68. PubMed ID: 19277004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L; Kubicka S
    Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunities for targeted therapies in hepatocellular carcinoma.
    Thomas MB; Abbruzzese JL
    J Clin Oncol; 2005 Nov; 23(31):8093-108. PubMed ID: 16258107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
    Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
    Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapies to extend survival in hepatocellular carcinoma.
    Gish R; Marrero JB; Tong MJ
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):1-14; quiz 15. PubMed ID: 18833600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatocellular carcinoma: current management and recent advances.
    Lau WY; Lai EC
    Hepatobiliary Pancreat Dis Int; 2008 Jun; 7(3):237-57. PubMed ID: 18522878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
    Hussain K; El-Serag HB
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):123-38. PubMed ID: 19305372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
    Kelley RK; Venook AP
    J Clin Oncol; 2008 Dec; 26(36):5845-8. PubMed ID: 19029408
    [No Abstract]   [Full Text] [Related]  

  • 39. Markedly effective local control of hepatocellular carcinoma with a poor prognosis by combined multimodal therapy with sorafenib as a neoadjuvant approach.
    Bathaix F; Marion D; Cuinet M; Maillard E; Zoulim F; Mornex F; Merle P
    Gastroenterol Clin Biol; 2010; 34(4-5):314-8. PubMed ID: 20207091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The treatment of hepatocellular carcinoma: an update].
    Vero V; Racco S; Biolato M; Pompili M; Gasbarrini G; Miele L; Grieco A
    Minerva Med; 2009 Jun; 100(3):173-93. PubMed ID: 19571783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.